IDEXX Director Szostak Exercises Options and Sells Shares on 08/22/2025
Rhea-AI Filing Summary
M. Anne Szostak, a director of IDEXX Laboratories, reported multiple transactions on 08/22/2025. She exercised a non-qualified stock option to acquire 2,187 shares at an exercise price of $206.62 per share and, on the same date, sold 2,187 shares at a weighted average price of $647.3252 per share. She also reported two gift transactions of 259 shares each: one reducing her direct holdings and one reflecting shares held by related trusts/foundations. Following the reported transactions, the filing shows 2,449 shares held directly and identified indirect interests via a trust and a family foundation.
Positive
- Exercise of non-qualified option fully disclosed: 2,187 shares acquired at $206.62 (08/22/2025)
- Trust/foundation relationships disclosed: Reporting person identifies trustee/settlor roles and nature of indirect ownership
Negative
- Insider sale of 2,187 shares: sold at a weighted average price of $647.3252 (08/22/2025)
- Reduction in direct holdings due to gifts: 259 shares transferred, reflecting movement out of direct ownership
Insights
TL;DR: Director exercised options and sold the same number of shares the same day, leaving modest direct and indirect holdings.
The filing documents a routine insider exercise of a non-qualified stock option for 2,187 shares at an exercise price of $206.62 and an immediate sale of 2,187 shares at a weighted average price of $647.3252. The exercise and sale are clearly disclosed and accompanied by small, documented gift transfers of 259 shares to related entities. For investors, this is a clear disclosure of insider liquidity and movement of shares between personal and affiliated accounts; no additional financial metrics or corporate actions are included in the filing.
TL;DR: Transactions are standard insider reporting: option exercise, sale, and documented gifts with trustee relationships disclosed.
The report identifies the reporting person as both settlor and trustee of a named trust and trustee of a family foundation, and it discloses the nature of indirect beneficial ownership for those entities. The filing includes an explanation of the weighted average sale price and offers to provide per-price details upon request, meeting disclosure expectations for Section 16 reporting. There are no indications of unusual or undisclosed arrangements in the text provided.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right-to-buy) | 2,187 | $0.00 | -- |
| Exercise | Common Stock | 2,187 | $206.62 | $452K |
| Sale | Common Stock | 2,187 | $647.3252 | $1.42M |
| Gift | Common Stock | 259 | $0.00 | -- |
| Gift | Common Stock | 259 | $0.00 | -- |
Footnotes (1)
- Represents the weighted average price of the shares sold ranging from a low of $647.30 to a high of $647.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event was earlier. Not applicable.
